JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB2056

Anti-TRAIL 抗体

Anti-TRAIL antibody

Be the first to review this product! Submit a review

|

(7 Publications)

Rabbit Polyclonal TRAIL antibody. Suitable for WB, IHC-P and reacts with Human samples. Cited in 7 publications. Immunogen corresponding to Synthetic Peptide within Human TNFSF10 aa 250 to C-terminus.

別名を表示する

CD253, APO2L, TRAIL, TNFSF10, Tumor necrosis factor ligand superfamily member 10, Apo-2 ligand, TNF-related apoptosis-inducing ligand, Apo-2L, Protein TRAIL

4 Images
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) of human brain tissue staining TRAIL with ab2056 at 20µg/ml

Western blot - Anti-TRAIL antibody (AB2056)
  • WB

Unknown

Western blot - Anti-TRAIL antibody (AB2056)

Western Blot of human brain lysate labeling TRAIL with Anti-TRAIL antibody (ab2056) at (1) 2.5 and (2) 5 μg/ml.

All lanes:

Western blot - Anti-TRAIL antibody (ab2056)

Predicted band size: 32 kDa

false

Western blot - Anti-TRAIL antibody (AB2056)
  • WB

Unknown

Western blot - Anti-TRAIL antibody (AB2056)

Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein including extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml Western blot analysis of HeLa cell lysate containing 10, 2.5, or 1 ng of recombinant protein containing extracellular domain of TRAIL with anti-TRAIL at 1 µg/ml.

All lanes:

Western blot - Anti-TRAIL antibody (ab2056)

Predicted band size: 32 kDa

false

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)
  • IHC-P

Unknown

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-TRAIL antibody (AB2056)

Immunohistochemistry of TRAIL in human brain tissue with TRAIL antibody at 20 µg/ml.

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Human

アプリケーション

IHC-P, WB

applications

免疫原

Synthetic Peptide within Human TNFSF10 aa 250 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

P50591

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/500", "WB-species-notes": "<p>Gives a 32 kD band which represents the membrane-bound form of TRAIL.</p>", "IHCP-species-checked": "testedAndGuaranteed", "IHCP-species-dilution-info": "20 µg/mL", "IHCP-species-notes": "<p></p>" } } }

下記製品にもご興味をお持ちいただけるかもしれません:

AB46074

Human TRAIL ELISA Kit (CD253)

0

0 Reviews

製品ページを見る
こちらの製品も推奨する理由

この製品は、同様の実験や関連する研究で広く使用されていることから推奨させていただいております。

お客様の実験に適するかご確認いただくため、必ず製品データシートをご確認いただくことをお勧めいたします。ご不明点等ございましたら、テクニカルサポートチームまでお問い合わせください。

製品の詳細

Ligand for DR4 and DR5.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification
バッファー組成
pH: 7.2 Preservative: 0.02% Sodium azide
出荷温度
Blue Ice
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

TRAIL also known as TNF-related apoptosis-inducing ligand plays an important role in inducing apoptosis. This protein has a mass of around 32 kDa and is expressed across various tissues including immune cells. TRAIL interacts with specific receptors on the cell surface to initiate a signaling cascade that results in programmed cell death. It is an attractive therapeutic target because of its selective ability to induce apoptosis in cancer cells while sparing most normal cells.
Biological function summary

TRAIL's function extends beyond inducing cell death. It is an important member of the tumor necrosis factor (TNF) superfamily which regulates immune responses and inflammation. TRAIL can form a homotrimeric complex allowing it to bind effectively to death receptors on target cells specifically DR4 and DR5 triggering a series of downstream signaling events. This interaction is significant in modulating immune surveillance and tumor suppression.

Pathways

TRAIL is integral to both intrinsic and extrinsic apoptosis pathways. Through these pathways TRAIL is closely related to FADD and caspase-8 which are important for apoptosis induction. The extrinsic pathway involves binding to TRAIL death receptors leading to DISC formation while the intrinsic pathway involves mitochondrial events mediated by members of the Bcl-2 protein family.

TRAIL has a significant connection with cancer and autoimmune diseases. TRAIL plays a dual role in cancer where it acts as a tumor suppressor but can also promote tumor progression if cancer cells become resistant to its effects. In cancer TRAIL’s interaction with proteins like FLIP can alter the apoptotic potential of the cells. In autoimmune diseases TRAIL's dysregulation can contribute to tissue damage due to increased immune activity highlighting its complex role in maintaining immune balance.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Cytokine that binds to TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and possibly also to TNFRSF11B/OPG (PubMed : 10549288, PubMed : 26457518). Induces apoptosis. Its activity may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4 and TNFRSF11B/OPG that cannot induce apoptosis.
See full target information TNFSF10

文献 (7)

Recent publications for all applications. Explore the full list and refine your search

International journal of oncology 63: PubMed37503786

2023

Modulation of PD‑L1 expression by standard therapy in head and neck cancer cell lines and exosomes.

Applications

Unspecified application

Species

Unspecified reactive species

Annette Affolter,Kai Liebel,Luisa Tengler,Elena Seiz,Moritz Tiedtke,Alexya Azhakesan,Julia Schütz,Marie-Nicole Theodoraki,Johann Kern,Arne M Ruder,Jens Fleckenstein,Cleo-Aron Weis,Karen Bieback,Benedikt Kramer,Anne Lammert,Claudia Scherl,Nicole Rotter,Sonja Ludwig

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 34:211-220 PubMed36511604

2022

Raw Lacquer Extract from Toxicodendron vernicifluum in Combination with ONC201 Enhances the Inhibitory Effects on Colorectal Cancer Cell Activity.

Applications

Unspecified application

Species

Unspecified reactive species

Zhezhu Jin,Yongjun Jin

Marine drugs 20: PubMed36286419

2022

Cytotoxic Potential of the Marine Diatom : Insights into Bioactivity of 24-Methylene Cholesterol.

Applications

Unspecified application

Species

Unspecified reactive species

Adele Cutignano,Mariarosaria Conte,Virginia Tirino,Vitale Del Vecchio,Roberto De Angelis,Angela Nebbioso,Lucia Altucci,Giovanna Romano

Cancers 13: PubMed33922569

2021

Small Extracellular Vesicles in Pre-Therapy Plasma Predict Clinical Outcome in Non-Small-Cell Lung Cancer Patients.

Applications

Unspecified application

Species

Unspecified reactive species

Eleni-Kyriaki Vetsika,Priyanka Sharma,Ioannis Samaras,Alexandra Markou,Vassilis Georgoulias,Theresa L Whiteside,Athanasios Kotsakis

Oncotarget 9:27233-27241 PubMed29930761

2018

Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations.

Applications

Unspecified application

Species

Unspecified reactive species

Matias Eliseo Melendez,Renato José Silva-Oliveira,Anna Luiza Silva Almeida Vicente,Lidia Maria Rebolho Batista Arantes,Ana Carolina de Carvalho,Alberto Luis Epstein,Rui Manuel Reis,André Lopes Carvalho

Clinical cancer research : an official journal of the American Association for Cancer Research 23:4843-4854 PubMed28400428

2017

Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer.

Applications

Unspecified application

Species

Unspecified reactive species

Sonja Ludwig,Theofanis Floros,Marie-Nicole Theodoraki,Chang-Sook Hong,Edwin K Jackson,Stephan Lang,Theresa L Whiteside

Oncology reports 27:39-44 PubMed21993926

2011

TRAIL produced from multiple myeloma cells is associated with osteolytic markers.

Applications

Unspecified application

Species

Unspecified reactive species

Yawara Kawano,Shikiko Ueno,Masahiro Abe,Yoshitaka Kikukawa,Hiromichi Yuki,Kenichi Iyama,Yutaka Okuno,Hiroaki Mitsuya,Hiroyuki Hata
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

関連製品

Select an associated product type
Alternative Product
Primary Antibodies

AB9959

Anti-TRAIL antibody

primary-antibodies

trail-antibody-ab9959

4

(1 reviews)

Alternative Product
Primary Antibodies

AB2219

Anti-TRAIL antibody [2E5]

primary-antibodies

trail-antibody-2e5-ab2219

0

(0 reviews)

Alternative Product
Primary Antibodies

AB95532

PE Anti-TRAIL antibody [N2B2]

primary-antibodies

pe-trail-antibody-n2b2-ab95532

0

(0 reviews)

Alternative Product
Primary Antibodies

AB42121

Anti-TRAIL antibody

primary-antibodies

trail-antibody-ab42121

1

(1 reviews)

Alternative Product
Primary Antibodies

AB231063

Anti-TRAIL antibody

primary-antibodies

trail-antibody-ab231063

0

(0 reviews)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com